Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd Share Price Today: Live Updates & Key Insights

Get insights on Ind-Swift Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Ind-Swift Laboratories Ltd Share Price Chart

Ind-Swift Laboratories Ltd Fundamentals

Traded Volume: 2,99,536

Market Cap(Cr): 821

Avg Traded Price 100.90

1 Year return -2.09%

Upper Circuit 105.6

Lower Circuit 95.3

P/E TTM 3.00

P/B Ratio 29.00

Traded Value(Cr) 301.21

EPS TTM 29.290

Book value 29.290

Dividend 0.00%

Ind-Swift Laboratories Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Ind-Swift Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Ind-Swift Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -2.77%

1M -4.06%

3M +0.50%

1Y -2.09%

YTD -13.37%

Ind-Swift Laboratories Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Ind-Swift Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 59831.00

Day Before Yesterday 78919.00

1W Avg 1.03L

1M Avg 76748.52

3M Avg 61422.10

Ind-Swift Laboratories Ltd Technical Details

Ind-Swift Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 95

Support 2 90

Support 3 85

Pivot Point : 100

Resistance 1 106

Resistance 2 111

Resistance 3 116

Ind-Swift Laboratories Ltd Corporate Actions

Ind-Swift Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Ind-Swift Laboratories Ltd’s capital allocation strategies.

All

Ex-Date 20-Sep-2011 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 16-Sep-2010 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 17-Sep-2009 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 18-Sep-2008 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 21-Sep-2007 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Dividends

Announcement Date 20-Sep-2011 Ex Dividend Date 20-Sep-2011 Dividend(%) 10

Announcement Date 16-Sep-2010 Ex Dividend Date 16-Sep-2010 Dividend(%) 10

Announcement Date 17-Sep-2009 Ex Dividend Date 17-Sep-2009 Dividend(%) 10

Announcement Date 18-Sep-2008 Ex Dividend Date 18-Sep-2008 Dividend(%) 10

Announcement Date 21-Sep-2007 Ex Dividend Date 21-Sep-2007 Dividend(%) 10

Bonus

No Bonus has been declared by INDSWFTLAB

Splits

No Split has been declared by INDSWFTLAB

Others

Rights No Rights has been declared by INDSWFTLAB

Ind-Swift Laboratories Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Ind-Swift Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Ind-Swift Laboratories Ltd's relative performance and valuation against major competitors.

Stock Name NGL Fine Chem Ltd ₹1348.00 (-3.15%) M. Cap (Cr) 8.33 1 Yr Return (%) -24.97% P/E (TTM) 40.26 PB Ratio 2.95

Stock Name Sakar Healthcare Ltd ₹372.40 (-4.88%) M. Cap (Cr) 8.29 1 Yr Return (%) +30.74% P/E (TTM) 42.48 PB Ratio 3.13

Stock Name Anlon Healthcare Ltd ₹155.06 (-0.81%) M. Cap (Cr) 8.24 1 Yr Return (%) NaN% P/E (TTM) PB Ratio 8.79

Stock Name Ind-Swift Laboratories Ltd ₹100.56 (+5.53%) M. Cap (Cr) 8.21 1 Yr Return (%) -2.09% P/E (TTM) 3.43 PB Ratio 0.79

Stock Name Fermenta Biotech Ltd ₹277.00 (-0.56%) M. Cap (Cr) 8.15 1 Yr Return (%) -15.25% P/E (TTM) 7.32 PB Ratio 2.83

Stock Name Remus Pharmaceuticals Ltd ₹695.05 (-4.42%) M. Cap (Cr) 8.19 1 Yr Return (%) -40.60% P/E (TTM) 28.17 PB Ratio 3.20

Stock Name Wanbury Ltd ₹229.50 (-0.33%) M. Cap (Cr) 8.01 1 Yr Return (%) +7.52% P/E (TTM) 15.97 PB Ratio 19.59

Ind-Swift Laboratories Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Ind-Swift Laboratories Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 -39.15 Mar 2024 -179.77 Mar 2023 182.67 Mar 2022 136.26 Mar 2021 135.03

PARTICULARS Investing Activities Mar 2025 -109.67 Mar 2024 -104.32 Mar 2023 -13.69 Mar 2022 2.76 Mar 2021 -10.17

PARTICULARS Financing Activities Mar 2025 74.22 Mar 2024 699.86 Mar 2023 -168.41 Mar 2022 -139.59 Mar 2021 -123.75

PARTICULARS Net Cash Flow Mar 2025 -74.60 Mar 2024 415.77 Mar 2023 0.58 Mar 2022 -0.57 Mar 2021 1.11

Ind-Swift Laboratories Ltd Shareholding Pattern

This shows the ownership breakdown of Ind-Swift Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 39.5%

Public 45.02%

Other Institutions 0.68%

FII 14.8%

Mutual Funds null%

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India. The Company is one of the leading manufacturers of APIs catering to global and domestic formulators. Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards. Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide.Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company.During the year 2003-04, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They launched four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (anti-hyperlipidemic), Anastrazole (oncology) and Nitazoxanide (anti-diarroheal). In January 2, 2004, the company incorporated a wholly owned subsidiary, namely Ind-Swift Laboratories Inc in USA to strengthen the company's presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations.During the year 2004-05, the company expanded the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market. During the year 2005-06, the company completed and commissioned their new plant at Samba in Jammu & Kashmir to manufacture products for the domestic markets. Also, they set up a new state of the art Research & Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA.During the year, the company launched new products namely, Letrozole, Anastrozole (Anti-Cancer) Venlafaxine (Anti-Depressants) Lavofloxacin (Anti-Biotic) Quetipine & Aripirazole (Anti-Pshychotic) in the market. They entered into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to focus on the marketing of the products in Middle East & Iran. During the year 2006-07, the company expanded the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids.During the year 2007-08, the company entered into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mint-based products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.During the year 2010, Company incorporated two new subsidiaries one in Dubai under the name of M/s Ind-Swift Middle East FZE,UAE and Second in Singapore under the name of M/s Ind-Swift Laboratories Pte Ltd., Singapore. The company launched new drugs likeDutasteride Cinacalcet, Duloxetine, Mecloxamine citrate, Atomoxetine, Exemestane, Ezetimibe, Pregabalin, Ranolazine, Telmisartan & Posaconazole in 2010. It commercialized the production of Mecloxamine citrate, Bexarotene and Dutasteride, developed new processes for key intermediates of Sunitinib and Mitiglinide calcium and robust and reproducible process developed for polymorph FORM I of Rifaximin in year 2011. During the financial year 2013, the Company had transferred its investment in Iran Joint Venture to its Dubai Subsidiary, which already completed the process of disinvestment.During the year 2013-14, 16,92,725 equity shares were allotted on 3rd February, 2014 on preferential basis to promoters and promoter group company at a price of Rs.55/- per share (including premium of Rs.45/- per share) and consequent to the allotment the paid up share capital of the Company stand at Rs.40,96,31,950/- consisting 4,09,63,195/- equity shares of Rs.10/- each.During 2015-16, 3 new products Nateglinide, Ezitimibe and Rosuvastatin were launched commercially and Lisdexamphentamine, a new product was supplied in the bio-batch quantities.During 2019-20, Mohali Green Environment Private Limited (MGEPL) ceased to be an Associate Company as Company's investment in MGEPL fell from 25.30% to 19.95%. as on 31st March, 2020.During 2020-21, Fortune (India) Constructions Limited (100%) and Halcyon Life Sciences Pvt. Ltd. (98.19%) became the wholly ownedsubsidiary of the company consequent to the Company acquiring/ subscribing to the total equity capital of these Companies. Fortune(India) Constructions Limited ceased to be the associate as it became the wholly owned subsidiary of the company.As on 31.03.2021, Company had 5 Subsidiaries i.e. Ind-Swift Laboratories Inc. (US Subsidiary), Ind-Swift Middle East FZ-LLC (Dubai Subsidiary), Meteoric Life Sciences PTE Ltd. (Singapore Subsidiary), Fortune (India) Constructions Limited (Indian Subsidiary) and Halcyon Life Sciences Pvt Ltd (Indian Subsidiary).During the Year 2021-22, M/s Meteoric Life Sciences Pte Ltd ceased to be a subsidiary of the Company with effect from August 10, 2021and M/s Ind-Swift Middle East FZE ceased to be subsidiary of the Company with effect from May 27, 2021 consequent to its sale to M/s. Soft Air General Trading LLC, UAE. The Company entered two Joint Ventures to enter into & explore new avenues available in the pharma fields. One joint venture was with M/s Wellgen Medicare LLP a Delhi based pharma trading concern and Mr. Anshul Jain on a 50:50 partnership basis a LLP named Indis Healthcare LLP. The Company also entered into an another joint venture with Mr. Ramesh Mehta as the partner on a 75:25 partnership basis by incorporating a private Company named MJM Remedies Private Limited.In FY 2024, the Company sold its complete API business & CRAMS business via slump-sale deal to PI Industries, effective on March 18, 2024. Further, the Company also incorporated ISLL Middle East L.L.CFZ, wholly owned subsidiary in Dubai on 17-05-2024.The group Company, Ind-Swift Limited got merged with the Company, making the Scheme of Amalgamation effective from August 8, 2025.

Chairman & Managing Director

N R Munjal

Registered office SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

FAX :91-0172-5061850/2730920

Background

Incorporation Year 1995

Face Value ₹10.00

Market Lot 1

Ind-Swift Laboratories Ltd Latest News

VIEW MORE NEWS

FAQs on Ind-Swift Laboratories Ltd